“The next generation of innovative, bio-based film technology has arrived,” says Milan Moscaritolo, Senior Director of Sales and Marketing of Toray Plastics. The company based in North Kingstown (Rhode Island, US) announced the introduction of new bio-based lidding films.
LumiLid® bio-based, dual-ovenable lidding films are manufactured with Toray’s proprietary sustainable resin blends, which are made with more than 50 percent renewable feedstocks. Bio-based LumiLid films were created to lessen the impact on the environment, as they use fewer petroleum resources while they are being manufactured, and to meet the needs of environment-conscious end users and consumers.
In addition – the company states – like all LumiLid films, these are solvent-free and may alleviate end-users’ concerns about solvent retention, as well as enhance the films’sustainability profile.
The new LumiLid films are designed for frozen, wet and dry food, and dairy applications. They are FDA-compliant for use with oven temperatures of up to 400°F for 30 minutes. LumiLid films are also Interstate Milk Shippers (IMS)-certified, so they offer another level of assurance for dairy customers.
According to Moscaritolo, “the option to choose a bio-based lidding film that has so many advanced features and such high-performance capability presents a unique opportunity to end users and converters.”
LumiLid bio-based films have the same superior performance qualities that are characteristic of the LumiLid brand. They have a low seal initiation (SIT), broad seal range, outstanding seal integrity, and an easy peel. They are available in clear, white, and metallized formats.
Toray Plastics is a subsidiary of Toray Industries, Inc., headquartered in Tokyo, Japan, and the world leader in high-performance films, synthetic fibers and textiles, carbon fibers, plastics, chemicals, and pharmaceuticals. Toray Industries was established in 1926 as Toyo Rayon Company and today operates 127 facilities in 18 countries with over 36,000 employees and annual sales exceeding US$19 billion.
IL BIOECONOMISTA 